<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03225261</url>
  </required_header>
  <id_info>
    <org_study_id>173003</org_study_id>
    <nct_id>NCT03225261</nct_id>
  </id_info>
  <brief_title>The Effect of Citrus Extract on Gastrointestinal Health</brief_title>
  <official_title>The Effect of Citrus Extract Administration on Gastrointestinal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, parallel, double-blind, placebo-controlled trial aims to determine the&#xD;
      effects of daily administration of citrus extract over a period of 8 weeks on&#xD;
      gastrointestinal health in patients with irritable bowel syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Actual">February 13, 2021</completion_date>
  <primary_completion_date type="Actual">February 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect on intestinal inflammation, measured by fecal calprotectin levels.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary objective is to assess the effect of 500 mg citrus extract on intestinal flammation after 8 weeks of administration, by measuring fecal calprotectin in IBS patients with moderately increased fecal calprotectin levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect on microbial metabolic activity, measured by fecal short chain fatty acids (SCFA).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on fecal microbiota composition, assessed by next generation sequencing.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on fecal microbiota functional capacity, assessed by next generation sequencing.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on the systemic immune response, measured by cytokine production capacity of stimulated whole blood</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on disease symptoms, measured by patient reported outcomes (GSRS).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on disease symptoms, measured by patient reported outcomes (symptom diary).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on stool frequency, measured by Bristol Stool Chart.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on stool consistency, measured by Bristol Stool Chart.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on blood markers for oxidative stress, measured by MDA concentration in blood.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect on blood markers for antioxidant capacity, measured by blood total antioxidant capacity.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Citrus extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citrus extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citrus extract</intervention_name>
    <description>Citrus extract</description>
    <arm_group_label>Citrus extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with IBS&#xD;
&#xD;
          -  Calprotectin levels 15-150 Âµg/g feces&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  BMI &lt; 35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Comorbidities that may influence gut microbiota composition or which might limit&#xD;
             participation in or completion of the study protocol (to be decided by the principle&#xD;
             investigator)&#xD;
&#xD;
          -  Abdominal surgery interfering with gastrointestinal function (to be decided by the&#xD;
             principle investigator)&#xD;
&#xD;
          -  Use of immunosuppressive drugs within 3 months before study period&#xD;
&#xD;
          -  Use of other medication interfering with endpoints&#xD;
&#xD;
          -  Changes in medication that may significantly affect the study outcome according to the&#xD;
             investigator's judgment within 1 month prior to the study&#xD;
&#xD;
          -  Changes in clinical activity scores within 3 weeks prior to the study&#xD;
&#xD;
          -  Administration of investigational drugs or participation in any scientific&#xD;
             intervention study which may interfere with this study (to be decided by the principle&#xD;
             investigator) in the 180 days prior to the study&#xD;
&#xD;
          -  Use of dietary supplements containing antioxidants, minerals and vitamins&#xD;
&#xD;
          -  Excessive intake of foods with a high polyphenol concentration&#xD;
&#xD;
          -  Use of antibiotics within 3 months prior to the start of study&#xD;
&#xD;
          -  Use of pre-or probiotics within 1 month prior to the study&#xD;
&#xD;
          -  Use of oral corticosteroids within 1 month prior to the study&#xD;
&#xD;
          -  Blood donation within 1 month prior to the study&#xD;
&#xD;
          -  Known pregnancy or lactation.&#xD;
&#xD;
          -  Excessive drinking (&gt;20 alcoholic consumptions per week)&#xD;
&#xD;
          -  History of any side effects towards the intake of flavonoids or citrus fruits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ad Masclee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Yala Stevens</investigator_full_name>
    <investigator_title>MSc.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

